Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Common Equity (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Common Equity for 4 consecutive years, with $441.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 12.25% to $441.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $441.2 million, a 12.25% decrease, with the full-year FY2025 number at $441.2 million, down 12.25% from a year prior.
  • Common Equity was $441.2 million for Q4 2025 at Day One Biopharmaceuticals, down from $450.9 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $555.5 million in Q3 2024 to a low of $259.6 million in Q1 2022.
  • A 4-year average of $393.9 million and a median of $390.1 million in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: fell 28.01% in 2024, then surged 61.56% in 2025.
  • Day One Biopharmaceuticals' Common Equity stood at $332.0 million in 2022, then grew by 4.37% to $346.5 million in 2023, then soared by 45.08% to $502.8 million in 2024, then dropped by 12.25% to $441.2 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Common Equity are $441.2 million (Q4 2025), $450.9 million (Q3 2025), and $460.8 million (Q2 2025).